Josep M Llovet

Author PubWeight™ 234.43‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Hepatocellular carcinoma. Lancet 2012 18.09
2 Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010 9.73
3 Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008 9.20
4 Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002 6.92
5 Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008 6.75
6 Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 2009 6.35
7 Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2008 5.93
8 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008 5.78
9 Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2006 5.17
10 Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology 2013 5.05
11 Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002 4.83
12 Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009 4.50
13 Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008 4.35
14 Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008 4.03
15 Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007 3.85
16 Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009 3.77
17 Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007 3.75
18 CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest 2009 3.62
19 Focus on hepatocellular carcinoma. Cancer Cell 2004 3.49
20 A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol 2009 3.44
21 Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012 3.04
22 Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004 2.89
23 Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011 2.85
24 Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest 2009 2.79
25 Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011 2.66
26 Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 2007 2.58
27 Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004 2.54
28 Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol 2012 2.53
29 Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010 2.46
30 Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol 2009 2.42
31 Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013 2.42
32 Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol 2011 2.39
33 Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006 2.38
34 Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009 2.38
35 A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology 2013 2.37
36 Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol 2008 2.22
37 Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 2013 2.21
38 Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 2013 2.13
39 Major achievements in hepatocellular carcinoma. Lancet 2009 2.10
40 Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol 2006 1.98
41 A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology 2009 1.90
42 Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 2010 1.86
43 MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003 1.85
44 Chemoembolization for intermediate HCC: is there proof of survival benefit? J Hepatol 2011 1.84
45 MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 2011 1.77
46 Staging systems in hepatocellular carcinoma. HPB (Oxford) 2005 1.71
47 Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology 2012 1.71
48 Cancer gene discovery in hepatocellular carcinoma. J Hepatol 2010 1.68
49 IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 2010 1.66
50 High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl 2004 1.65
51 Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004 1.65
52 Experimental models of hepatocellular carcinoma. J Hepatol 2008 1.61
53 Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol 2012 1.57
54 Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol 2009 1.52
55 New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 2010 1.46
56 Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res 2012 1.44
57 Induction of hepatocellular carcinoma by in vivo gene targeting. Proc Natl Acad Sci U S A 2012 1.31
58 Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol 2008 1.26
59 Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol 2012 1.26
60 Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma. Gastroenterology 2013 1.26
61 Treatment of hepatocellular carcinoma: is there an optimal strategy? Cancer Treat Rev 2003 1.25
62 Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology 2008 1.21
63 Molecular profiling to predict hepatocellular carcinoma outcome. Expert Rev Gastroenterol Hepatol 2009 1.17
64 Hepatitis B virus and hepatocellular carcinoma. J Hepatol 2003 1.14
65 HCC surveillance: who is the target population? Hepatology 2003 1.12
66 Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. Hepatology 2011 1.07
67 Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib. Clin Cancer Res 2012 1.05
68 Molecular approaches to treatment of hepatocellular carcinoma. Dig Liver Dis 2010 1.01
69 Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol 2012 1.01
70 Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision. Liver Transpl 2003 0.98
71 Two decades of advances in hepatocellular carcinoma research. Semin Liver Dis 2010 0.94
72 Molecular diagnosis of chronic liver disease and hepatocellular carcinoma: the potential of gene expression profiling. Semin Liver Dis 2006 0.94
73 Obesity, inflammatory signaling, and hepatocellular carcinoma-an enlarging link. Cancer Cell 2010 0.92
74 Abdominal drainage after liver resection for hepatocellular carcinoma in cirrhotic patients: a randomized controlled study. Hepatogastroenterology 2004 0.92
75 Preoperative evaluation of biliary anatomy in adult live liver donors with volumetric mangafodipir trisodium enhanced magnetic resonance cholangiography. Liver Transpl 2004 0.91
76 Prognostic assessment and evaluation of the benefits of treatment. J Clin Gastroenterol 2002 0.90
77 Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. Hepatology 2012 0.88
78 Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 2015 0.88
79 p27(Kip1) is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma. J Hepatol 2003 0.86
80 Hepatocellular carcinoma: a clinical update. MedGenMed 2003 0.86
81 Molecular targeted therapies in hepatocellular carcinoma: from pre-clinical models to clinical trials. J Hepatol 2008 0.85
82 Gene expression profiles in hepatocellular carcinoma: not yet there. J Hepatol 2004 0.85
83 miRNA delivery: emerging therapy for hepatocellular carcinoma. Gastroenterology 2010 0.84
84 [Diagnosis and treatment of hepatocellular carcinoma]. Med Clin (Barc) 2009 0.84
85 Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma. J Natl Cancer Inst 2008 0.83
86 Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials. J Clin Oncol 2009 0.83
87 Lymphotoxins: new targets for hepatocellular carcinoma. Cancer Cell 2009 0.83
88 Percutaneous ethanol injection for hepatocellular carcinoma: alive or dead? J Hepatol 2005 0.82
89 A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis. Hepatology 2011 0.82
90 Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma. Hepatology 2012 0.82
91 Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal. Liver Transpl 2006 0.82
92 Risk factors for hepatocellular carcinoma in HCV-cirrhosis: what we know and what is missing. J Hepatol 2006 0.82
93 Liver transplantation in hepatocellular carcinoma. Transpl Int 2005 0.81
94 Hepatocellular carcinoma enters the sequencing era. Gastroenterology 2011 0.80
95 HCC Is promoted by bacterial translocation and TLR-4 signaling: a new paradigm for chemoprevention and management. Hepatology 2012 0.80
96 [Cell biology and genetics in liver cancer]. Gastroenterol Hepatol 2007 0.80
97 Hippo tumor supressor pathway: novel implications for the treatment of hepatocellular carcinoma. Gastroenterology 2010 0.79
98 Liver transplantation for hepatocellular carcinoma: is expansion of criteria justified? Clin Liver Dis 2005 0.79
99 Smoking, hepatitis B virus infection, and development of hepatocellular carcinoma. J Natl Cancer Inst 2011 0.79
100 Contrast-enhanced power Doppler sonography and helical computed tomography for assessment of vascularity of small hepatocellular carcinomas before and after percutaneous ablation. J Clin Ultrasound 2003 0.79
101 Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization. Radiology 2004 0.77
102 Molecular epidemiology in HCV-related hepatocellular carcinoma: first steps. J Hepatol 2012 0.77
103 Expected developments in hepatology. Best Pract Res Clin Gastroenterol 2002 0.77
104 Accomplishments in 2008 in the management of hepatobiliary cancers. Gastrointest Cancer Res 2009 0.76
105 Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma. J Hepatol 2011 0.75
106 Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies? J Hepatol 2013 0.75
107 Applicability of adult-to-adult living donor liver transplantation. J Hepatol 2005 0.75
108 microRNAs and the MYC network: a major piece in the puzzle of liver cancer. Gastroenterology 2011 0.75
109 Expanding HCC criteria for liver transplant: the urgent need for prospective, robust data. Liver Transpl 2006 0.75
110 Sunitinib and the benefits of a negative study. Lancet Oncol 2009 0.75
111 Corrigendum: Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature 2015 0.75